Oculis (NASDAQ:OCS) Earns “Buy” Rating from HC Wainwright

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $44.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 52.04% from the company’s current price.

A number of other equities analysts also recently weighed in on OCS. Stifel Nicolaus upped their price target on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Thursday, January 22nd. Needham & Company LLC upped their price target on shares of Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.86.

Oculis Price Performance

Shares of NASDAQ:OCS traded up $1.48 on Monday, reaching $28.94. 413,142 shares of the company traded hands, compared to its average volume of 308,113. Oculis has a fifty-two week low of $16.00 and a fifty-two week high of $30.68. The company’s 50 day moving average is $27.29 and its 200-day moving average is $23.54. The stock has a market capitalization of $1.68 billion, a PE ratio of -12.75 and a beta of 0.48. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.96 and a quick ratio of 5.96.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.14 million. As a group, analysts anticipate that Oculis will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Several hedge funds have recently bought and sold shares of OCS. Gildi lifeyrissjodur bought a new stake in Oculis during the fourth quarter valued at about $50,250,000. Aberdeen Group plc boosted its holdings in Oculis by 39.4% during the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after acquiring an additional 493,827 shares during the period. SR One Capital Management LP boosted its holdings in Oculis by 98.8% during the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after acquiring an additional 318,522 shares during the period. Perceptive Advisors LLC bought a new stake in Oculis during the fourth quarter valued at about $9,862,000. Finally, Alyeska Investment Group L.P. boosted its holdings in Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after acquiring an additional 200,000 shares during the period. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.